Conference Coverage

Pegloticase Decreases in MAP in Patients with Chronic Gout

New Orleans—In an analysis of results from randomized clinical trials of pegloticase, researchers examined the impact of persistent, very low levels of serum uric acid on blood pressure in patients with chronic refractory gout. The analysis included data on 29 responders whose mean arterial pressure (MAP) at baseline was 94.9 mm Hg. Throughout the 6-month trial, there were significant reductions ... Read More »

ADPKD Patients with Advanced CKD at Increased Risk of Adverse Outcomes

New Orleans—Patients with autosomal dominant polycystic kidney disease (ADPKD) develop progressive chronic kidney disease (CKD) and a subsequent increased risk for adverse events that include cardiovascular disease, infections, end-stage renal disease (ESRD), and mortality. There are few data available on the risks of adverse events in patients with ADPKD and advanced CKD. Manish M. Sood, MD, and colleagues conducted a ... Read More »

Fluid Overload and AKI and Mortality in Influenza Patients

New Orleans—In a subset of critically ill patients with influenza, particularly A(H1N1), the influenza virus has been consistently associated with high mortality in patients who develop Acute Distress Respiratory Syndrome (ADRS).  There are few available data on the risk factors for this association. There have been studies documenting the association of fluid overload and an increase in the incidence of ... Read More »

Identifying Rapid Progression in Patients with ADPKD

New Orleans—The most frequently inherited kidney disease is autosomal dominant polycystic kidney disease (ADPKD). The progressive cyst growth associated with ADPKD, combined with interstitial damage, causes progressive kidney failure; there is wide variation of the severity of ADPKD among this patient population. The European Medicines Agency has approved tolvaptan for adults with CKD stage 1 to 3 at baseline who ... Read More »

Predicting Hyponatremia from Electronic Medical Records

New Orleans—In both hospitalized and ambulatory patients, hyponatremia is associated with increased morbidity and mortality. Utilizing electronic medical records (EMRs) to identify patients at high risk for hyponatremia may have significant impact on patient outcomes, according to Young-Il Jo, MD, and Sug kyun Shin, MD. Identification of high-risk patients can also serve to support clinical decision making the management of ... Read More »

Biomarkers for Early Diagnosis of AKI in Critically Ill Patients

New Orleans—Hospitalized patients may experience acute kidney injury (AKI), a condition that is more common among patients in the intensive care unit (ICU). Serum creatinine measurement can be used to assess AKI; however, according to Luana A. Pedroso, MD, and colleagues, serum creatinine is a poor and delayed marker of AKI. In recent decades, new circulating and urinary biomarkers have ... Read More »

Pathways and Biomarkers for Progression of Diabetic Kidney Disease

New Orleans—The leading cause of end-stage renal disease (ESRD) is diabetic kidney disease. According to researchers, understanding of molecular pathways involved in the initiation and progression of diabetic kidney disease facilitates development of biomarkers and identification of drug targets. Skander Mulder, MD, and colleagues conducted a study designed to identify molecular pathways associated with progressive loss of kidney function in ... Read More »

Size Mismatch in Pediatric Living Donor Kidney Transplantation

New Orleans—Previous studies have demonstrated an association between small donor body size in relation to recipient body size and increased risk of graft loss following kidney transplantation. There are few data, however, on this relationship in young children undergoing living donor kidney transplantation, a patient population with a greater possibility of size mismatch. Heather L. Wasik, MD, and colleagues at ... Read More »

Options Education Impacts Modality Choice for ESRD Patients

New Orleans—Patients with chronic kidney disease making decisions regarding options for renal replacement therapy (RRT) may be helped with the use of education programs on dialysis; however, there are few data on the impact of educational programs on modality choice. Yue Jiao, MD, and colleagues at Fresenius Medical Care North America (Waltham, MA) conducted an analysis designed to examine the ... Read More »

Tolvaptan Improved Hyponatremia in Patient with Melanoma

New Orleans—The 10-year survival rate for patients with metastatic melanoma is <10%. The majority of patients are treated with systemic therapy, and there are associations between immunotherapeutic agents and durable response in some patients. In 1998, the FDA approved high dose interleukin-2 (IL-2) for treatment of metastatic melanoma. Common adverse effects include fever, chills, hypotension, cardiac arrhythmias, oliguria, volume overload, ... Read More »